DJ Transaction in own shares
Arix Bioscience PLC (ARIX)
Transaction in own shares
21-May-2021 / 17:09 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Transaction in own shares
LONDON, 21 May 2021: Arix Bioscience plc ("Arix" or "the Company") (LSE: ARIX), a global venture capital company
focused on investing in and building breakthrough biotech companies, today announces that it purchased the following
number of its ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as
part of a buyback programme announced on 22 March 2021.
Date of purchase 21 May 2021
Aggregate number of shares purchased 60,000
Highest price paid per share 184.00p
Lowest price paid per share 184.00p
Average price paid per share 184.00p
Arix intends to retain the purchased shares in treasury.
Following settlement of the above purchase, Arix will have 132,288,800 ordinary shares of 0.001 pence each in issue (excluding 3,320,853 ordinary shares of 0.001 pence each held in treasury). This number represents the total voting rights in Arix and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), the schedule below contains detailed information of the individual trades made by Jefferies International Limited as part of the buyback programme.
[ENDS]
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Shabnam Bashir
+44 (0)20 3922 1906
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Transaction Date Transaction Time Volume Price (GBp) Platform Transaction Reference Number 21/05/2021 16:22:35 60,000 184.00 London Stock Exchange 00242137266TRLO1 ----------------------------------------------------------------------------------------------------------------------- ISIN: GB00BD045071 Category Code: POS TIDM: ARIX LEI Code: 213800OVT3AHQCXNIX43 OAM Categories: 2.4. Acquisition or disposal of the issuer's own shares Sequence No.: 106767 EQS News ID: 1199608 End of Announcement EQS News Service =------------------------------------------------------------------------------------ Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1199608&application_name=news
(END) Dow Jones Newswires
May 21, 2021 12:09 ET (16:09 GMT)
